In re Pfizer Inc. Sec. Litig.

E-Law Admin/ April 12, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

In re Pfizer Inc. Sec. Litig., 14-2853

In a securities class action, contending that Pfizer made fraudulent misrepresentations and omissions regarding the safety of Celebrex and Bextra in violation of section 10(b), section 20(a), and section 20A of the Securities Exchange Act, the district court’s grant of summary judgment to defendant is vacated and the case remanded where: 1) the district court improperly excluded plaintiff’s offered expert testimony on causation and damages; and 2) the district court erred in concluding that no reasonable jury could find defendant liable for statements made by companies at owned the drugs before defendant.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/04/12




  • United States Second Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar